Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

Basit Öğe Kaydı
dc.authorid0000-0002-9782-6807
dc.authorid0000-0001-8857-2983
dc.contributor.authorAcar, Caner
dc.contributor.authorYuksel, Haydar Cagatay
dc.contributor.authorSahin, Gokhan
dc.contributor.authorAcar, Fatma Pinar
dc.contributor.authorKaraca, Burcak
dc.date.accessioned2025-04-28T12:57:48Z
dc.date.available2025-04-28T12:57:48Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractHyperprogressive disease (HPD) is described as the unexpected rapid growth of a tumour accompanied by a decline in performance status. While immune checkpoint inhibitors (ICIs) have improved outcomes in advanced melanoma, HPD remains a significant challenge in a subset of patients. Although HPD has been extensively studied in various solid tumours, research specifically focusing on advanced melanoma remains limited. We analysed 158 advanced melanoma patients, with 66.5% (n = 105) receiving anti-PD-1 and 33.5% (n = 53) receiving nivolumab plus ipilimumab. The median overall survival was 4.9 months for patients with HPD compared to 8.9 months for those with progressive disease without HPD (p = 0.014). Factors associated with HPD included liver metastasis (p = 0.002), three or more metastatic sites (p < 0.001), elevated lactate dehydrogenase levels (p = 0.004), and Eastern cooperative oncology group performance status >= 2 (p = 0.023). Multivariate analysis identified the Royal Marsden Hospital score (HR 3.675, 95% CI: 1.166-11.580, p = 0.026) as an independent risk factor for HPD, with the MDA-ICI score also trending towards significance (HR 4.466, 95% CI: 0.947-21.061, p = 0.059). This study provides valuable insights into the frequency and factors associated with HPD in advanced melanoma patients treated with ICIs, highlighting the relevance of clinical markers and scoring systems in predicting HPD risk.
dc.identifier.citationAcar, C., Yuksel, H. C., Sahin, G., Acar, F. P., & Karaca, B. (2024). Exploring the frequency and risk factors of hyperprogressive disease in patients with advanced melanoma treated with immune checkpoint inhibitors. Current Oncology (Toronto), 31(10), 6343-6355
dc.identifier.doi10.3390/curroncol31100472
dc.identifier.endpage6355
dc.identifier.issn17187729
dc.identifier.issue10
dc.identifier.pmid39451776
dc.identifier.scopus2-s2.0-85207370718
dc.identifier.scopusqualityQ3
dc.identifier.startpage6343
dc.identifier.urihttps://doi.org/10.3390/curroncol31100472
dc.identifier.urihttps://hdl.handle.net/11454/117173
dc.identifier.volume31
dc.identifier.wosWOS:001343537200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAcar, Caner
dc.institutionauthorYuksel, Haydar Cagatay
dc.institutionauthorSahin, Gokhan
dc.institutionauthorAcar, Fatma Pinar
dc.institutionauthorKaraca, Burcak
dc.institutionauthorid0000-0002-9782-6807
dc.institutionauthorid0000-0001-8857-2983
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofCurrent Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectadvanced melanoma
dc.subjecthyperprogressive disease
dc.subjectimmune checkpoint inhibitors
dc.subjectoverall survival
dc.subjectrisk factors
dc.titleExploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu